CUE BIOPHARMA INC (CUE) Fundamental Analysis & Valuation

NASDAQ:CUE • US22978P1066

Current stock price

0.2642 USD
+0.01 (+3.65%)
At close:
0.2504 USD
-0.01 (-5.22%)
After Hours:

This CUE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

0

1. CUE Profitability Analysis

1.1 Basic Checks

  • In the past year CUE has reported negative net income.
  • In the past year CUE has reported a negative cash flow from operations.
  • In the past 5 years CUE always reported negative net income.
  • In the past 5 years CUE always reported negative operating cash flow.
CUE Yearly Net Income VS EBIT VS OCF VS FCFCUE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M -50M

1.2 Ratios

  • The Return On Assets of CUE (-63.02%) is worse than 60.89% of its industry peers.
  • CUE's Return On Equity of -100.64% is in line compared to the rest of the industry. CUE outperforms 44.89% of its industry peers.
Industry RankSector Rank
ROA -63.02%
ROE -100.64%
ROIC N/A
ROA(3y)-90.61%
ROA(5y)-76.57%
ROE(3y)-156.63%
ROE(5y)-123.6%
ROIC(3y)N/A
ROIC(5y)N/A
CUE Yearly ROA, ROE, ROICCUE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100 -150 -200

1.3 Margins

  • CUE does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CUE Yearly Profit, Operating, Gross MarginsCUE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. CUE Health Analysis

2.1 Basic Checks

  • CUE does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, CUE has more shares outstanding
  • CUE has more shares outstanding than it did 5 years ago.
  • The debt/assets ratio for CUE has been reduced compared to a year ago.
CUE Yearly Shares OutstandingCUE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
CUE Yearly Total Debt VS Total AssetsCUE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • CUE has an Altman-Z score of -12.18. This is a bad value and indicates that CUE is not financially healthy and even has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -12.18, CUE is doing worse than 76.88% of the companies in the same industry.
  • CUE has a Debt/Equity ratio of 0.03. This is a healthy value indicating a solid balance between debt and equity.
  • With a Debt to Equity ratio value of 0.03, CUE perfoms like the industry average, outperforming 45.28% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Altman-Z -12.18
ROIC/WACCN/A
WACC9.97%
CUE Yearly LT Debt VS Equity VS FCFCUE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M -40M 60M

2.3 Liquidity

  • A Current Ratio of 2.74 indicates that CUE has no problem at all paying its short term obligations.
  • The Current ratio of CUE (2.74) is worse than 67.63% of its industry peers.
  • A Quick Ratio of 2.74 indicates that CUE has no problem at all paying its short term obligations.
  • Looking at the Quick ratio, with a value of 2.74, CUE is doing worse than 64.93% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.74
Quick Ratio 2.74
CUE Yearly Current Assets VS Current LiabilitesCUE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. CUE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 58.19% over the past year.
  • The Revenue has grown by 195.75% in the past year. This is a very strong growth!
  • CUE shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 54.20% yearly.
EPS 1Y (TTM)58.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.52%
Revenue 1Y (TTM)195.75%
Revenue growth 3Y180.09%
Revenue growth 5Y54.2%
Sales Q2Q%1292.26%

3.2 Future

  • Based on estimates for the next years, CUE will show a decrease in Earnings Per Share. The EPS will decrease by -2.33% on average per year.
  • CUE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -34.02% yearly.
EPS Next Y-17.07%
EPS Next 2Y-1.21%
EPS Next 3Y37.25%
EPS Next 5Y-2.33%
Revenue Next Year25%
Revenue Next 2Y60.08%
Revenue Next 3Y89.51%
Revenue Next 5Y-34.02%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CUE Yearly Revenue VS EstimatesCUE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 20M 40M 60M 80M
CUE Yearly EPS VS EstimatesCUE Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 1 -1

More info and screens

Find the best growth stocksShow best growing peers

1

4. CUE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CUE. In the last year negative earnings were reported.
  • Also next year CUE is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CUE Price Earnings VS Forward Price EarningsCUE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CUE Per share dataCUE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.2 -0.2 -0.4

4.3 Compensation for Growth

  • A more expensive valuation may be justified as CUE's earnings are expected to grow with 37.25% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.21%
EPS Next 3Y37.25%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CUE Dividend Analysis

5.1 Amount

  • No dividends for CUE!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CUE Fundamentals: All Metrics, Ratios and Statistics

CUE BIOPHARMA INC

NASDAQ:CUE (3/25/2026, 8:19:44 PM)

After market: 0.2504 -0.01 (-5.22%)

0.2642

+0.01 (+3.65%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-24
Earnings (Next)05-06
Inst Owners27.67%
Inst Owner Change20.9%
Ins Owners0.51%
Ins Owner Change12.61%
Market Cap20.80M
Revenue(TTM)27.47M
Net Income(TTM)-26.60M
Analysts80
Price Target4.08 (1444.28%)
Short Float %2.28%
Short Ratio1.55
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)380.95%
Min Revenue beat(2)-7.09%
Max Revenue beat(2)768.99%
Revenue beat(4)2
Avg Revenue beat(4)179.23%
Min Revenue beat(4)-67.11%
Max Revenue beat(4)768.99%
Revenue beat(8)5
Avg Revenue beat(8)121.29%
Revenue beat(12)8
Avg Revenue beat(12)85.76%
Revenue beat(16)9
Avg Revenue beat(16)51.44%
PT rev (1m)-20%
PT rev (3m)-20%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.49%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-36.3%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.76
P/FCF N/A
P/OCF N/A
P/B 0.79
P/tB 0.79
EV/EBITDA N/A
EPS(TTM)-0.31
EYN/A
EPS(NY)-0.48
Fwd EYN/A
FCF(TTM)-0.28
FCFYN/A
OCF(TTM)-0.28
OCFYN/A
SpS0.35
BVpS0.34
TBVpS0.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.02%
ROE -100.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-90.61%
ROA(5y)-76.57%
ROE(3y)-156.63%
ROE(5y)-123.6%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.65
Health
Industry RankSector Rank
Debt/Equity 0.03
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 18.48%
Cap/Sales 0.64%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.74
Quick Ratio 2.74
Altman-Z -12.18
F-Score6
WACC9.97%
ROIC/WACCN/A
Cap/Depr(3y)11.7%
Cap/Depr(5y)25.16%
Cap/Sales(3y)0.45%
Cap/Sales(5y)4.21%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)58.19%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%111.52%
EPS Next Y-17.07%
EPS Next 2Y-1.21%
EPS Next 3Y37.25%
EPS Next 5Y-2.33%
Revenue 1Y (TTM)195.75%
Revenue growth 3Y180.09%
Revenue growth 5Y54.2%
Sales Q2Q%1292.26%
Revenue Next Year25%
Revenue Next 2Y60.08%
Revenue Next 3Y89.51%
Revenue Next 5Y-34.02%
EBIT growth 1Y36.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y39.93%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y40.3%
OCF growth 3YN/A
OCF growth 5YN/A

CUE BIOPHARMA INC / CUE Fundamental Analysis FAQ

What is the fundamental rating for CUE stock?

ChartMill assigns a fundamental rating of 2 / 10 to CUE.


Can you provide the valuation status for CUE BIOPHARMA INC?

ChartMill assigns a valuation rating of 1 / 10 to CUE BIOPHARMA INC (CUE). This can be considered as Overvalued.


What is the profitability of CUE stock?

CUE BIOPHARMA INC (CUE) has a profitability rating of 0 / 10.


What is the earnings growth outlook for CUE BIOPHARMA INC?

The Earnings per Share (EPS) of CUE BIOPHARMA INC (CUE) is expected to decline by -17.07% in the next year.